Scalper1 News
Today’s IBD 50 roundup features five top drugmakers that have been making headlines. Even though they’ve all now extended past buying range, they may yet form new bases, and investors won’t want to be late to blink-and-you’ll-miss-it key price ranges. Specialty drugmaker Akorn (AKRX) has been on a bit of a ride lately. After climbing out of an area of consolidation in early February, Akron choppily hovered around a buy range before reaching a new Scalper1 News
Scalper1 News